Arrowhead Pharmaceuticals Applies to New Zealand Regulator for Trial of ARO-DIMER-PA to Treat Mixed Hyperlipidemia
MT Newswires Live
Yesterday
Arrowhead Pharmaceuticals (ARWR) said Tuesday it has requested regulatory clearance from New Zealand's Medicines and Medical Devices Safety Authority to conduct a phase 1/2a clinical trial of ARO-DIMER-PA to treat patients with atherosclerotic cardiovascular disease due to mixed hyperlipidemia.
Mixed hyperlipidemia patients have elevated low-density lipoprotein cholesterol and triglyceride levels, a major risk factor for atherosclerotic cardiovascular disease, the company said, adding that it is the leading cause of death in the world.
The company said the trial, if approved, will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and effects of ARO-DIMER-PA on low-density lipoprotein cholesterol and triglyceride levels.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.